Business Wire08.01.18
Implanet, a medical technology company specializing in vertebral and knee-surgery implants, has announced its establishment in Germany.
Following the opening of the Implanet U.K. sales branch in June 2018, Implanet continues direct operational expansion in the European market at a rapid pace with the opening of Implanet GmbH, in Frankfurt am Main. Implanet targets the German degenerative spine disease market, the largest in Europe, estimated at 300 million dollars,1 with approximately 1,000 potential surgeon customers. Like Implanet U.K., this new German branch will capitalize on the success of Implanet’s strategy in France and the United States by setting up a mixed network of direct sales representatives and exclusive sales agents.
Implanet GmbH is headed by Jana Heuer, with 10 years of experience as a sales leader in the spinal surgery market, most recently at Paradigm Spine for four years and K2M for six years.
CEO Ludovic Lastennet said, “After announcing Implanet U.K. in June, the opening of Implanet GmbH in Germany represents a new milestone in the implementation of our 2018-2019 strategic plan: this consists in promoting Implanet’s product range directly in key European markets and preparing to integrate the products of our partner L&K Biomed.”
Founded in 2007, IMPLANET is a medical technology company that manufactures implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the U.S. Food and Drug Administration and the CE mark. IMPLANET employs 46 staff and recorded 2017 sales of 7.8 million euros.
Based near Bordeaux in France, IMPLANET established a U.S. subsidiary in Boston in 2013.
Following the opening of the Implanet U.K. sales branch in June 2018, Implanet continues direct operational expansion in the European market at a rapid pace with the opening of Implanet GmbH, in Frankfurt am Main. Implanet targets the German degenerative spine disease market, the largest in Europe, estimated at 300 million dollars,1 with approximately 1,000 potential surgeon customers. Like Implanet U.K., this new German branch will capitalize on the success of Implanet’s strategy in France and the United States by setting up a mixed network of direct sales representatives and exclusive sales agents.
Implanet GmbH is headed by Jana Heuer, with 10 years of experience as a sales leader in the spinal surgery market, most recently at Paradigm Spine for four years and K2M for six years.
CEO Ludovic Lastennet said, “After announcing Implanet U.K. in June, the opening of Implanet GmbH in Germany represents a new milestone in the implementation of our 2018-2019 strategic plan: this consists in promoting Implanet’s product range directly in key European markets and preparing to integrate the products of our partner L&K Biomed.”
Founded in 2007, IMPLANET is a medical technology company that manufactures implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the U.S. Food and Drug Administration and the CE mark. IMPLANET employs 46 staff and recorded 2017 sales of 7.8 million euros.
Based near Bordeaux in France, IMPLANET established a U.S. subsidiary in Boston in 2013.